What This Bill Does
This bill reauthorizes the C.W. Bill Young Cell Transplantation Program and increases its funding from the current $31,009,000 to $33,009,000 per year for fiscal years 2027 through 2031. It also extends the cord blood inventory program from 2026 to 2031. The main people affected are patients who need stem cell or cord blood transplants, donors, transplant centers, and the federal program that maintains matching and inventory systems.
- Raises annual funding for the C.W. Bill Young Cell Transplantation Program to $33,009,000 for fiscal years 2027 through 2031.
- Keeps the program’s funding authorization in the Public Health Service Act, 42 U.S.C. 274m.
- Extends the cord blood inventory deadline from 2026 to 2031.
- Continues federal support for the national system used to help match transplant patients with stem cell and cord blood units.
Who This Bill Affects
For the general public, this bill has a limited but real health-policy effect: it keeps federal support flowing to the national stem cell transplantation program and extends the cord blood inventory through 2031. If you or a family member ever need a blood stem cell or cord blood transplant, the bill helps preserve the system that searches for and maintains matching units, backed by $33,009,000 a year from fiscal 2027 through 2031. For most people, the direct day-to-day effect is indirect rather than immediate, but it supports access for patients facing serious blood disorders or cancers.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Patients with blood cancers or serious blood disorders They benefit from a stronger, longer-lasting national transplant system that can help identify compatible stem cell or cord blood matches. Extending the program through 2031 improves continuity for people who may need urgent transplants.
- Transplant hospitals and clinicians Hospitals rely on a stable federal inventory and matching infrastructure to find suitable donor material. The reauthorization and annual funding level give providers certainty for planning and patient care.
- Cord blood banks and biomedical researchers A longer inventory authorization helps preserve and expand access to stored cord blood units and supports ongoing research and transplantation use. Continued federal funding can keep the system operational and scientifically useful.
- Fiscal conservatives They may object to extending federal spending at $33,009,000 per year through 2031, especially for a specialized program that serves a relatively narrow patient population. They may prefer shorter authorizations or lower spending levels.
- Budget hawks seeking program consolidation They may argue that the federal government should scale back or consolidate specialized health inventories rather than repeatedly reauthorizing them. From this view, the bill locks in spending without a broader redesign of transplant support.
- Critics of long-term program extensions They may prefer shorter renewals so Congress can reassess the program sooner. A five-year extension of both funding and cord blood inventory authority reduces opportunities for near-term review and restructuring.
Key Implications
-
““$33,009,000 for each of fiscal years 2027 through 2031””
This sets a specific annual federal funding level for five years, which gives the transplant program longer-term budget certainty. It also signals that Congress intends the program to continue operating rather than lapse after the next fiscal year.
-
““Cord blood inventory ... by striking ‘2026’ and inserting ‘2031’””
This pushes the inventory program’s expiration date back five years. For patients who depend on cord blood as a transplant source, that means the federal inventory system stays in place longer.
-
““C.W. Bill Young Cell Transplantation Program””
The bill does not create a new program; it renews an existing one. That matters because the legislation is about continuity of services and financing, not a new benefit category.
-
““read twice and referred to the Committee on Health, Education, Labor, and Pensions””
This shows the bill is moving through the Senate’s health committee process. The committee’s role is where most of the substantive work on reauthorization bills happens.
Latest Status
June 17, 2026
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.